Tourmaline Bio Inc reports results for the quarter ended December 31 - Earnings Summary

Tourmaline Bio

17/03/2025 13:31

Tourmaline Bio Inc TRML.OQ reported a quarterly adjusted loss of 86 cents​​ per share for the quarter ended December 31, lower than the same quarter last year, when the company reported EPS of -81 cents.  The mean expectation of ten analysts for the quarter was for a loss of 87 cents per share. Wall Street expected results to range from $-1.22 to -75 cents per share.

Reported revenue was zero​; analysts expected zero.

Tourmaline Bio Inc's reported EPS for the quarter was a loss of 86 cents​.

The company reported a quarterly loss of $22.24 million.

Tourmaline Bio Inc shares had fallen by 7.3% this quarter.

FORECAST CHANGES

The mean earnings estimate of analysts had risen by about 1.5% in the last three months.​

In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 10 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

Wall Street's median 12-month price target for Tourmaline Bio Inc is $55.00

This summary was machine generated from LSEG data March 17 at 01:31 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

QUARTER ENDING
ESTIMATE
ACTUAL
BEAT, MET, MISSED
Dec. 31 2024
-0.87
-0.86
Beat
Sep. 30 2024
-0.82
-0.78
Beat
Jun. 30 2024
-0.71
-0.68
Beat
Mar. 31 2024
-0.67
-0.55
Beat